14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ITRM vs OVID: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Ovid Therapeutics Inc. (OVID) is the stronger overall head-to-head candidate over Iterum Therapeutics plc Ordinary Share (ITRM) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ITRM carries a Unified Composite Score of 50.5/100 (HOLD) at $0.03 (N/M Forward P/E, -1982.3% operating margin), whereas OVID carries 52.3/100 (HOLD) at $2.20 (1.8x Forward P/E, -4693.7% operating margin).
Technical & Structure Timing Caution: ITRM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9); meanwhile OVID is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ITRM vs OVID. Trailing 12-month operating profitability (ITRM -1982.3% vs OVID -4693.7%) and valuation multiples (ITRM N/M vs OVID 1.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $424.6M market capitalization and -4693.7% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ITRM vs OVID Key Questions & Quantitative Answers
As of Nov 20, 2026, Ovid Therapeutics Inc. (OVID) is the stronger overall head-to-head candidate over Iterum Therapeutics plc Ordinary Share (ITRM) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ITRM carries a Unified Composite Score of 50.5/100 (HOLD) at $0.03 (N/M Forward P/E, -1982.3% operating margin), whereas OVID carries 52.3/100 (HOLD) at $2.20 (1.8x Forward P/E, -4693.7% operating margin). Technical & Structure Timing Caution: ITRM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9); meanwhile OVID is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
OVID leads the Growth & Scale pillar: ITRM posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on $390,000 TTM revenue (29.7% gross margin, -1982.3% operating margin), compared with OVID at -88.3% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (100.0% gross margin, -4693.7% operating margin). On trailing 12-month operating scale, ITRM generates $390,000 in USD-normalized revenue versus $1.5M for OVID. In operating R&D and SG&A reinvestment, ITRM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OVID.
OVID screens cheaper on headline valuation multiples. ITRM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin), whereas OVID trades at 1.8x Forward P/E, 1.8x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ITRM (-555.7% ROE) versus OVID (-35.4% ROE) capital efficiency.
In options market volatility and institutional positioning, ITRM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.61β · 508% Vol realized risk). By comparison, OVID carries 11.7% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.04β · 97% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.